Emanuele Gabellieri received a PhD in pharmaceutical chemistry from the Faculty of Pharmacy, University of Siena under the supervision of Prof. Campiani. He started his drug discovery career in 2007 with the medicinal chemistry group at Siena biotech, where he contributed to the identification of an inhibitor for the beta-amyloid producing enzyme BACE-1, which entered in Phase 1 trials in 2012. After one year as an organic process chemist he moved to AC IMMUNE in 2013. He began working on diagnostic projects for the development of imaging markers and is currently leading a multidisciplinary project team aimed at the discovery of new small molecules for the treatment of neuroinflammatory diseases. Dr. Gabellieri has authored more than 29 papers and patents and has more than 13 years of experience in CNS drug discovery projects through all the discovery phases with the generation of clinical candidates reaching the clinical trials.